Weaver Consulting Group Argenx Se Transaction History
Weaver Consulting Group
- $293 Million
- Q4 2024
Shares
4 transactions
Others Institutions Holding ARGX
# of Institutions
434Shares Held
28.8MCall Options Held
390KPut Options Held
272K-
Price T Rowe Associates Inc Baltimore, MD5.52MShares$3.25 Billion0.39% of portfolio
-
Artisan Partners Limited Partnership Milwaukee, WI3.07MShares$1.81 Billion3.02% of portfolio
-
Janus Henderson Group PLC London, X02.31MShares$1.36 Billion0.76% of portfolio
-
Capital World Investors Los Angeles, CA1.79MShares$1.05 Billion0.17% of portfolio
-
Avoro Capital Advisors LLC New York, NY1.24MShares$730 Million11.1% of portfolio
About ARGENX SE
- Ticker ARGX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 55,323,800
- Market Cap $32.6B
- Description
- argenx SE, a biotechnology company, focuses on developing various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany and France. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, ...